Get notified of page updates

Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through clinicaltrials.gov.

Search Results: (30 results)

91 through 120 of 162
Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)


Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)

This study looks at how well omega-3 fatty acid ethyl esters (generic Lovaza) work in preventing colorectal cancer in patients with Lynch syndrome. Omega-3 fatty acids work by decreasing inflammation, or swelling, in the body, and suppressing certain chemicals in the body that are known to cause cancer. The addition of omega-3 fatty acids to patients' diets may help decrease colon inflammation or suppress cancer-causing chemicals in the body. NOTE: This study is no longer enrolling people. 

More info
Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation

Treatment

A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO)

The usual approach for patients with curable (i.e., non-metastatic) pancreatic cancer is a combination of surgery, FDA-approved chemotherapy, radiation (in select cases), then surveillance monitoring. This means that patients are typically monitored by their oncologist for evidence that the cancer has returned (recurrence), but they receive no additional treatment after the completion of surgery and chemotherapy.

The purpose of EA2192 / APOLLO is to compare the usual approach (observation) to treatment for one year with a drug called olaparib, in patients with BRCA1, BRCA2 or PALB2 mutation. EA2192 / APOLLO will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if olaparib delays cancer recurrence compared to the usual approach of surveillance.

More info
Research Study to Help Improve Family Communication About Inherited BRCA1 or BRCA2 Mutations

Prevention

Research Study to Help Improve Family Communication About Inherited Mutations

The Ohio State University and FORCE want to understand if a family communication guide for people with BRCA mutations is helpful and if it’s also useful to have a video that you can text or email to family members that explains your BRCA mutation. We are currently looking for people between the ages of 18-80 who have mutation in BRCA1 or BRCA2, have an active email address, and an internet capable device like a computer, tablet, or smartphone.  Participants will be asked to complete a total of 3 surveys.  Participants will be randomly assigned to either receive just the communication guide or the guide plus the sharable.  Each survey will take 10-15 minutes (the study could take up to 1.5 hours to complete depending on how much time you spend reviewing the study materials). 

You can get more information or ask to participate in the study by sending an email to: brcashare@osumc.edu.

More info
Phase 1 Study of Oral Drug PMD-026 in People With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer


Phase 1/1b Study of Oral Drug PMD-026 in People with Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

PMD-026 is a study for people who have been diagnosed with metastatic triple negative breast cancer (mTNBC) who have no further treatment options. This research study is investigating if a study drug called PMD-026 is safe and effective for patients with mTNBC. NOTE: This study is no longer enrolling. 

More info
Addition of Pembrolizumab to Radiation Treatment for Newly Diagnosed Early Stage MSI-High Endometrial Cancer


Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

The purpose of this study is to determine whether the addition of the immunotherapy agent pembrolizumab to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer recurrence in patients with newly diagnosed stage I-II endometrial cancer that is MSI-High. This study is no longer enrolling.

More info
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Treatment

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

This study will look at how well PARP inhibitor olaparib works in treating women or men who have been diagnosed with biliary tract (bile duct) cancer that has metastasized to other places in the body and who also have DNA repair gene mutations that give them a higher risk of certain cancers.  Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

More info
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer or Checkpoint Inhibitor Relapsed Tumors

Treatment

A Study of EDP1503 in Patients With Colorectal or Triple Negative Breast Cancer or Cancer That Came Back After Treatment with a Checkpoint Inhibitor

Medicines that affect bacteria in the stomach and intestines may assist immunotherapy agents like pembrolizumab (Keytruda) in treating cancer. This study will look at the effect of a drug, EDP1503 on enhancing the anti-cancer response when used with pembrolizumab, in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, or cancers that have recurred after a type of immunotherapy known as an immune checkpoint inhibitor. NOTE: This this study is no longer enrolling patients. 

More info
Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families

Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation

Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)

The goal of MiDe is to develop a clinical diagnostic test to detect early onset ovarian cancer, as currently, there are no good screening or early detection tests available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US. 

More info
Nivolumab, Nivolumab Plus Ipilimumab, or Chemotherapy for Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (CheckMate 8HW)

Treatment
People with metastatic colorectal cancer that is MSI-High

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)

The purpose of this study is to compare the benefit of the combination of immunotherapy agents Nivolumab plus Ipilimumab in patients who have Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer versus using Nivolumab as a single therapy or chemotherapy. 

More info
Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy

Treatment

Pembrolizumab and Olaparib for People With Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy

This is a study for people diagnosed with metastatic pancreatic cancer with Homologous Recombination Deficiency, or whose disease has responded well to first-line or second-line platinum therapy. The goal of this study is to look at whether combining the immunotherapy drug, pembrolizumab and the PARP inhibitor, olaparib is a more effective treatment for this cancer than taking olaparib alone.

 

More info
RESTORE: A virtual study comparing 2 digital apps to improve mental and physical well-being of patients with stage I – 3 cancer


People with stage 1-3 cancer

RESTORE: A virtual study comparing 2 digital apps to improve mental and physical well-being of patients with stage I – 3 cancer

Many cancer patients experience cancer-related distress, which includes psychological symptoms of anxiety and depression. The RESTORE study will enroll up to 415 adults who have been diagnosed with stage I-III cancer. The goal is to test how effective two different apps are at improving physical and mental health. Participants use their smartphone or tablet to download and access their assigned treatment app without ever needing to visit a clinic in person.

More info
PARP Inhibitor for Metastatic Prostate Cancer With DNA Repair Defects

Treatment

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

This is a phase II study looking at different treatment combinations for men with metastatic, castration resistant prostate cancer (mCRPC) to see which is most effective for improving progression free survival (keeping the cancer from progressing). The study will include testing for genes within the tumor to determine eligibility for the study. 

Patients with tumors that have ATM, BRCA1 and/or BRCA2 mutations or defects will be randomly assigned to one of the treatment arms of the study. Patients with tumors that have mutations in other DNA repair genes including FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2, MSH6, BRIP1, or FAM175A will be assigned to Arm IV with single agent olaparib.

More info
Mobile Mindfulness Meditation Intervention to Improve Neuropathy in Cancer Survivors

Quality of Life

Mobile Mindfulness Meditation Intervention to Improve Neuropathy in Cancer Survivors

Aloha! The University of Hawai‘i Cancer Center is running a mobile app study to see how it impacts cancer-related neuropathy. We are asking people who have been diagnosed with cancer, have finished primary treatment and are experiencing neuropathy if they would like to use a mobile app for mindfulness meditation to see if it helps their neuropathy.  

Interested participants will be asked to follow the link for either anxiety OR neuropathy and to participate in only one of the studies, one time only. Upon enrollment, you will randomly be assigned to begin using the mobile app either immediately or after eight weeks. You will be asked to complete online questionnaires about your well-being upon your initial enrollment, 8 weeks later, and 16 weeks later.

More info
Niraparib + Ipilimumab or Nivolumab in Pancreatic Cancer that Has Not Progressed After Platinum Chemotherapy (Parpvax)


Niraparib + Ipilimumab or Nivolumab in Pancreatic Cancer that Has Not Progressed After Platinum Chemotherapy (Parpvax)

The purpose of this study is to look at the effectiveness, safety, and anti-cancer activity of the drug Niraparib combined with one of two immunotherapy agents: Ipilimumab or Nivolumab on patients with locally advanced or metastatic pancreatic cancer.  Patients in this study must also have previously received Platinum-based chemotherapy without evidence of disease progression.  NOTE: This study is no longer enrolling patients. 

More info
Parenting Adolescent-Aged Children While Managing a Parental Cancer Diagnosis – Share Your Story


Parenting Adolescent-Aged Children While Managing a Parental Cancer Diagnosis – Share Your Story

The study explores how families faced with a parental cancer diagnosis communicate, or why they choose not to communicate, with their children about the cancer diagnosis, treatments, and other related topics. At least one family member (diagnosed parent or non-diagnosed parent) is asked to participate, but more than one member can sign up to be interviewed. NOTE: This study is no longer enrolling people. 

More info
Mobile Mindfulness Meditation Intervention for Cancer Survivors

Quality of Life

Mobile Mindfulness Meditation Intervention to Improve the Well-Being of Cancer Survivors

Aloha! The University of Hawai‘i Cancer Center is running a mobile app study to see how it impacts different areas of well-being in cancer survivors – namely, anxiety and cancer-related neuropathy. We are asking people who have been diagnosed with cancer and finished primary treatment if they would like to use a mobile app for mindfulness meditation to see if it impacts anxiety.  

Interested participants will be asked to follow the link for anxiety. Upon enrollment, you will randomly be assigned to begin using the mobile app either immediately or after eight weeks. You will be asked to complete online questionnaires about your well-being upon your initial enrollment, 8 weeks later, and 16 weeks later.

More info
A Survey on Options for Managing Cancer Risk Among Women with a BRCA1 or BRCA2 Mutation

Surveys, Registries, Interviews

A Survey on Options for Managing Cancer Risk Among Women with a BRCA1 or BRCA2 Mutation

Women with a BRCA1 or BRCA2 mutation are at higher risk of developing breast and/or ovarian cancer compared to women in the general population. There are various options available to these women to help reduce or manage these risks, including preventive surgery. We are conducting an important new study to examine and understand cancer prevention decisions and outcomes in these women.

More info
Nous-209 Genetic Vaccine for the Treatment of MSI-H Colorectal, Gastric and Gastro-esophageal junction Tumors

Treatment
Treatment study for people with advanced colorectal, gastric and gastro-esophageal junction tumors

Nous-209 Genetic Vaccine for the Treatment of Microsatellite -High (MSI-H) Colorectal, Gastric and Gastro-esophageal junction Tumors

The goal of this cancer treatment study is to find the best dose and learn how safe and effective this cancer vaccine is for treating advanced colorectal, gastric and gastro-esophageal junction tumors that test positive for the biomarkers MSI-High or dMMR. Participants will receive the vaccine in combination with the immunotherapy drug Keytruda (pembrolizumab). 

More info
TRITON3- Rucaparib vs. Physician Choice for Castration Resistant Prostate Cancer

Treatment

A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

The purpose of Triton3 is to determine how patients with metastatic castration-resistant prostate cancer, and an inherited gene mutation or tumor genetic deficiency, respond to treatment with the PARP inhibitor rucaparib compared to treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel. NOTE: This study is no longer enrolling patients. 

More info
Blood Tests to Measure Ovarian Reserves in Women with a BRCA Mutation or Women Treated for Early-Stage Breast Cancer


Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations

The purpose of this study is to see how cancer treatment affects the ovaries, such as the impact on conceiving a child or the early onset of menopause. Comparatively, the study will also look at high-risk women with BRCA1/2 mutations (and no evidence of breast or ovarian cancer).

The study will check blood levels of hormones that the ovaries produce and will use questionnaires to gather information about participant menstrual cycles, health, and pregnancies. 

More info
Olaparib Expanded - Treating Metastatic Breast Cancer in People without gBRCA Mutations

Treatment

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

Olaparib Expanded is a study looking at whether the drug Olaparib is effective treatment for people with certain types of metastatic breast cancer.  Olaparib belongs to a class of drugs known as PARP inhibitors. PARP inhibitors are particularly effective for treating tumors in people with an inherited BRCA mutation. This study is looking at whether olaparib is also effective for treating metastatic breast cancer in people who do not have an inherited BRCA mutation. Currently the study is only recruiting people with an inherited PALB2 mutation or people who test negative for an inherited mutation in BRCA1 or BRCA2 but have an acquired (somatic) BRCA1 or BRCA2 mutation found on tumor testing. 

More info
The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations

Surveys, Registries, Interviews

The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations

Those who carry the BRCA1, BRCA2 or PALB2 gene mutations experience a higher lifetime risk of developing breast and ovarian cancer, but we need to know more about the other genetic and non-genetic factors that may also influence risk. This study follows women with these gene mutations over time, striving to build the evidence we need to help them and others make better decisions to protect their health.

More info
Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS)


Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS)

Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS) is a national, patient-driven registry for any male who has undergone or is currently undergoing genetic testing for prostate cancer. Note: This study is no longer enrolling. 

 

More info
Combination Immunotherapies in Patients Who Previously Received Immune Checkpoint Inhibitors (QUILT-3.055)

Treatment

A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment with Immune Checkpoint Inhibitors (QUILT-3.055)

Immune checkpoint inhibitors immunotherapy drugs that allow the immune system to find and destroy cancer cells.

This study will use a combination of immunotherapies in people who's cancer got worse after treatment with a PD-1 or PD-L1 immune checkpoint inhibitor. NOTE: This study is no longer recruiting.

More info
Diagnosis of Breast Cancer in Young Women - Share Your Story

Surveys, Registries, Interviews

Diagnosis of Breast Cancer in Young Women - Share Your Story

Researchers from the University of Illinois, Chicago Cancer Center invite breast cancer survivors who were diagnosed under the age of 45 to share their diagnosis stories. You will be asked to use your own words to share your experience on an online questionnaire. 

More info
Olaparib Combined with Agents Targeting DNA Damage Repair Compared to Olaparib Alone

Treatment

Safety and Efficacy of Olaparib Combined with Agents Targeting DNA Damage Repair Compared to Olaparib Alone

The purpose of this study is to assess the efficacy and safety of treatment with the PARP inhibitor, olaparib combined with the drug Ceralasertib compared with olaparib alone for patients with Triple-Negative Breast Cancer.

NOTE: This study is no longer enrolling patients. 

More info
Studying a Combination of Immunotherapies and Biomarker for Advanced Solid Tumors

Treatment

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden

This study is researching a combination of two immunotherapy drugs for advanced solid tumors that contain a tumor biomarker known as "High Tumor Mutation Burden" (TMB-H). The researchers are studying whether treatment  of these tumors with a combination of the drugs nivolumab plus ipilimumab is safe and effective compared with nivolumab alone. NOTE: This study is no longer enrolling.

More info
Talazoparib for people with metastatic breast cancer who have acquired (somatic) BRCA mutations

Treatment

Talazoparib for people with metastatic breast cancer who have acquired (somatic) BRCA mutations

This is a study for patients with metastatic breast cancer who do not have an inherited mutation in BRCA1 or BRCA2 but who are are found to have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy. Patients are treated with talazoparib, a well-tolerated oral PARP inhibitor that targets the BRCA1/2 mutation to determine whether this treatment (which is already approved for germline BRCA1/2 carriers) is effective in this population.

More info
A Study of Nivolumab in Selected Uterine Cancer Patients


A Study of Nivolumab in Selected Uterine Cancer Patients

The purpose of this study is to test the effectiveness, safety, and tolerability of Nivolumab on patients with metastatic or recurrent uterine cancer. 

Nivolumab is a type of immunotherapy known as an immune checkpoint inhibitor. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.  NOTE: This study is no longer enrolling. 

More info
GENERATE


GENetic Education Risk Assessment and TEsting Study (GENERATE)

The goal of the GENERATE study is to increase the uptake of genetic testing among family members of pancreatic cancer patients who may carry a genetic mutation.

This study involves education about genetic testing, undergoing genetic testing for cancer risk (for those who choose to) and completion of a series of 4 sets of questionnaires. Note: This study is no longer enrolling patients.

 

More info
Additional Results on Clinicaltrials.gov
1000 results
Clinical Trial Official Title
NCT04703920 Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
NCT05457842 A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery
NCT05394259 A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
NCT05061017 Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
NCT04930783 NeoVax + CDX-301 and Nivolumab in Advanced Melanoma
NCT03929029 Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
NCT04117087 Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer
NCT04655157 Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma
NCT05057715 huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
NCT05034536 Pembrolizumab + Infliximab for Metastatic Melanoma
NCT03104439 Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
NCT01638676 A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
NCT04598009 Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
NCT03454035 Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
NCT02870244 Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
NCT04315233 Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
NCT05388851 Education for Prevention of Melanoma in Hispanic Populations
NCT04592861 Carbon Ion RT for Locally Advanced Pancreatic Cancer
NCT04024878 NeoVax With Nivolumab in Patients With Ovarian Cancer
NCT04996823 Axitinib + Ipilimumab in Advanced Melanoma
NCT04339140 Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer
NCT04611568 War on Melanoma™ Public Health & Education Campaign
NCT04552223 Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
NCT05308901 Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
NCT02621021 A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
NCT04971499 A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
NCT05130177 Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
NCT04581382 Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
NCT04570553 Use of an Intrauterine Manipulator and Its Correlation With Positive Peritoneal Cytology in Early Stage Endometrial Cancers
NCT03950635 Dietary Intervention in Patients With a History of Melanoma
NCT03311308 A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
NCT04930991 High Dose Omeprazole in Patients With Pancreatic Cancer
NCT04464759 A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
NCT03757689 Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma
NCT02706353 APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
NCT04526730 Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
NCT05272462 Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer
NCT04020809 Neoadjuvant Atezolizumab in Cutaneous Melanoma
NCT03935256 Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer
NCT03092453 Dendritic Cell Vaccination in Patients With Advanced Melanoma
NCT03765229 An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma
NCT05384496 Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
NCT03743766 Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
NCT01972919 Magnetic Resonance (MR) Guided, Dose-Escalated Radiation Therapy (RT) + Chemotherapy in Pancreatic Cancer
NCT05089370 Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma
NCT03842943 Neoadjuvant Combination Immunotherapy for Stage III Melanoma
NCT05029154 Exercise Preconditioning in Ovarian Cancer
NCT04493203 Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
NCT04688658 Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
NCT04633902 Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
NCT04513028 Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
NCT04048278 Lidocaine Infusion in Pancreatic Cancer
NCT05546827 PRISM: Pre-Operative Radiotherapy and Immunotherapy for Sinonasal Melanoma
NCT03925350 Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
NCT05047926 Prehabilitation for Advanced Ovarian Cancer Patients
NCT03957551 Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
NCT02143050 Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
NCT05438927 Early Supportive Care and Nutritional Support in Adults With Pancreatic Cancer
NCT05524935 Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
NCT05188586 New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)
NCT03322995 Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer
NCT04476537 RNA Precision Oncology in Advanced Pancreatic Cancer
NCT05077280 A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma
NCT05004025 Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma
NCT05200143 Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
NCT05483075 Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer
NCT04318717 Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
NCT04177810 Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
NCT04187833 Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
NCT02041936 Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System
NCT04970368 Comparison of Nodal Staging in Endometrial Cancer
NCT03492164 In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer
NCT03256201 Exercise and Nutrition to Improve Pancreatic Cancer Outcomes
NCT04783467 Time Restricted Eating (TRE) Among Endometrial Cancer Patients
NCT05360732 Redefining FOLFIORINOX in Older Pancreatic Cancer Patients
NCT04390880 18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer
NCT04683653 Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT05170334 Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
NCT04927013 Connecting Families to Overcome Ovarian Cancer
NCT04820179 Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
NCT04025229 High Intensity Interval Training in Endometrial Cancer
NCT04458402 Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer
NCT03287271 ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
NCT04473833 Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
NCT04844970 Anamorelin Study for Advanced Pancreatic Cancer
NCT04386993 De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer
NCT04720417 Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
NCT04608409 Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
NCT05316129 Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
NCT04427306 Neoadjuvant T-VEC in High Risk Early Melanoma
NCT04594187 Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
NCT05123807 Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
NCT05189457 First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
NCT05586360 T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer
NCT03932409 Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NCT03832361 Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
NCT03385486 Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
NCT03232164 PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
NCT05098210 Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer
NCT02672098 Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
NCT04984343 Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer
NCT05229588 Lurbinectedin in Patients With Advanced Pancreatic Cancer With DNA Repair Mutations
NCT03467516 Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
NCT03617328 Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
NCT03323944 CAR T Cell Immunotherapy for Pancreatic Cancer
NCT03541928 Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
NCT03769766 Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
NCT03674814 Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
NCT04346225 Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer
NCT05470036 Improving Germline Testing in At-Risk Patients With Prostate Cancer
NCT04700332 PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
NCT04928508 Advanced or Recurrent Ovarian, Cervical, and Endometrial Cancer Treated With SHetA2
NCT04903119 Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma
NCT02340117 Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
NCT02128100 Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer
NCT04011410 Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
NCT02282137 68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer
NCT03783325 Assessing Gene-Environment Interactions in Clinical Presentation of Nevi and Melanoma
NCT04179968 The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer
NCT03743298 Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
NCT03617679 Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
NCT03951831 REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
NCT03646617 Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
NCT05470283 Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
NCT05496686 Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
NCT03991130 High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
NCT04528199 [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
NCT04093323 Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
NCT04741997 Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
NCT04562129 IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
NCT05318131 Sleep, Exercise, Nutrition and Survivorship in Prostate Cancer
NCT03955978 TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
NCT05289193 CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
NCT03734692 Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
NCT04665947 First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
NCT03679260 Carbohydrate Restricted Diet Intervention for Men on Prostate Cancer Active Surveillance
NCT02331134 Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
NCT04019964 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
NCT05056896 ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension
NCT04364230 Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
NCT04981223 Predicting Location and Extent of Prostate Cancer Using Micro-Ultrasound Imaging
NCT03223779 Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
NCT05454488 An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer
NCT04457089 Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
NCT05477823 Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
NCT04082962 Dexamethasone Implant for Retinal Detachment in Uveal Melanoma
NCT03694834 Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer
NCT05375539 AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients
NCT05099679 Pilot Study for Optimizing Mental Wellbeing & Heart Health for Black Patients w/ Prostate Cancer
NCT04144127 Soccer Intervention in Prostate Cancer Survivors
NCT04825288 XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
NCT04635059 Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
NCT05345444 Feasibility Study of Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)
NCT04588025 Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response
NCT04842890 Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer
NCT04116775 Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
NCT04552509 TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
NCT04705038 Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
NCT04349501 Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
NCT05224869 Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer
NCT04167969 The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer
NCT04037358 RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
NCT03665922 Biomarkers of Sulforaphane/Broccoli Sprout Extract in Prostate Cancer
NCT03392181 PET/MRI for the Staging of Newly Diagnosed Prostate Cancer
NCT05608694 MRI Screening in Men at High Risk of Developing Prostate Cancer
NCT04989946 Androgen Deprivation, With or Without pTVG-AR, and With or Without Nivolumab, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
NCT05068752 Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
NCT03971591 Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors
NCT03275857 Cisplatin in Castration Resistant Prostate Cancer
NCT05417386 FOLFIRINOX + NIS793 in Pancreatic Cancer
NCT04298983 Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer
NCT03999151 Diet and Exercise Interventions Among Men With Prostate Cancer (Prostate 8-II)
NCT03585660 Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy
NCT04147806 A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer
NCT03315871 Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
NCT05026983 Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
NCT02705196 LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
NCT02016248 Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer
NCT04301414 Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
NCT05141643 Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer
NCT04904120 Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
NCT03663218 PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT)
NCT04402151 Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
NCT03089203 CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer
NCT03619655 Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
NCT02933255 PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
NCT03753243 Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
NCT03730948 DC Vaccine in Colorectal Cancer
NCT04422132 Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks
NCT03863457 [18F] F-GLN by PET/CT in Breast Cancer
NCT05489991 A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05011188 FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
NCT05013216 Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
NCT02207465 A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
NCT02600156 Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors
NCT05111353 Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
NCT05304962 First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
NCT03596073 Topical Calcipotriene Treatment for Breast Cancer Immunoprevention
NCT01607008 MRI for Assessing Prostate Cancer Response
NCT03495427 PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
NCT04360330 SABER Study for Selected Early Stage Breast Cancer
NCT02946996 Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
NCT05156905 Study of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
NCT02382549 A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
NCT05396872 Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer
NCT04039230 Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
NCT03087903 A Study of Grape Seed Extract in Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising PSA
NCT05393713 Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for the Treatment of In-Transit Melanoma, The Sofusa-2 Study
NCT04220983 PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer
NCT03959891 AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
NCT04401995 Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab
NCT02926729 Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
NCT04536077 Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
NCT00588185 [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
NCT03861975 Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening
NCT04692675 Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
NCT01088789 A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine
NCT05497778 A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
NCT03486821 Ultra-hypofractionated Radiation in Prostate Cancer
NCT05073432 Development of a Personalized Discussion Prioritization Tool for Older Adults Considering Adjuvant Chemotherapy for Breast Cancer
NCT05304936 HCW9218 for Advanced Pancreatic Cancer
NCT05504707 DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
NCT05628883 Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
NCT04670068 Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
NCT02420977 Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer
NCT03769155 VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
NCT04743999 Evaluation of Quality of Life Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma
NCT03652428 Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
NCT05077098 Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer
NCT04502602 Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer
NCT03765983 GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
NCT02040610 Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer
NCT05086250 Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
NCT03553602 BEACON: HDR Brachytherapy, EBRT and STAD for the Treatment of Local and Pelvic Recurrence of Prostate Cancer After Radiation Therapy
NCT04651452 Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors
NCT04158635 Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
NCT05014776 Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
NCT03860987 Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
NCT05327452 Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study
NCT05327465 Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
NCT05051631 BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
NCT04754191 Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT05085548 ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
NCT05219500 Targeted Alpha Therapy With 225Actinium-PSMA-I&T of Castration-resISTant Prostate Cancer (TATCIST).
NCT05528133 Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
NCT04109729 Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
NCT03763838 Acupressure for Fatigue in Ovarian Cancer Survivors
NCT04477512 Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
NCT03543969 Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
NCT04206319 Radium-223 in Biochemically Recurrent Prostate Cancer
NCT05472064 Design of Chatbot Persona for Breast Cancer Screening Outreach Among Black Women
NCT04132505 Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
NCT05424783 MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
NCT05519449 Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
NCT04883814 18F-fluoroestradiol (FES) PET/CT for Breast Cancer
NCT04158245 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
NCT03564782 Examining Bioactivity of PVSRIPO in Invasive Breast Cancer
NCT05243524 Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer
NCT03212170 FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer
NCT03761706 Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of Aging
NCT04420702 Diffusion Basis Spectrum Imaging of the Prostate
NCT05263492 Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
NCT05324098 Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy
NCT04483414 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer
NCT04786600 A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
NCT03965481 PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer
NCT04228055 Comprehensive Lifestyle Improvement Program for Men With Prostate Cancer2 (CLIPP2)
NCT04270149 Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer
NCT05412225 A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
NCT04452357 Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer
NCT05025735 Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
NCT02515513 The Role of Muscle Cachexia in Pancreatic Cancer
NCT04848051 Implementing Fit Kit Colorectal Cancer (CRC) Screening in High Risk Populations
NCT05378464 Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
NCT05064410 Screen to Save: NCI Colorectal Cancer Outreach & Screening Initiative
NCT05064085 Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer
NCT02564848 Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65
NCT03668431 Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
NCT04450264 Increasing African Immigrant Women's Participation in Breast Cancer Screening
NCT05419817 Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
NCT05338307 Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer Prevention
NCT03742245 Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
NCT04465500 EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
NCT04728633 Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
NCT04967196 Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
NCT02643667 Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
NCT05343013 TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
NCT03068624 Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
NCT04336397 Stool DNA to Improve Colorectal Cancer Screening Among Alaska Native People
NCT03694756 TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
NCT04940442 Outreach and Choice in Colorectal Cancer Screening
NCT04192071 Virtual Human Delivered Nutrition Module for Colorectal Cancer Prevention
NCT04282967 Streaming Web-based Exercise At Home: A Pilot Study
NCT00734838 Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy
NCT05337280 OA for Breast Cancer NAC Response
NCT01952730 GVAX for Colorectal Cancer
NCT03321188 Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
NCT05611931 Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05052723 Cabozantinib and Pembrolizumab in Metastatic Pancreas
NCT04768426 Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
NCT04997096 Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NCT05361798 T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
NCT04474184 Development of a New Early Detection Test to Reduce Racial Disparities in Endometrial Cancer (EC) Death Rates
NCT05092763 Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian Cancer
NCT05446129 A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery
NCT05081193 Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
NCT05607095 Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma
NCT05571839 A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
NCT05113485 UCLA Breast Cancer Survivor Health Promotion Research Study
NCT04965064 Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
NCT05127850 MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer
NCT04262180 Physical Activity Promotion for Breast and Endometrial Cancer Survivors
NCT05000502 Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations
NCT05334732 Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)
NCT03312972 Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy
NCT03496805 Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
NCT05036226 COAST Therapy in Advanced Solid Tumors and Prostate Cancer
NCT05444231 An Online Research Study: BrainHealth in Breast Cancer Survivors
NCT05336786 An Imaging Agent (Perflutren Lipid Microspheres) With Ultrasound for Imaging of Prostate Cancer
NCT03253744 Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
NCT04914663 All-extremity Exercise During Breast Cancer Chemotherapy
NCT04013568 Exercise Post-Diagnosis of Breast Cancer
NCT03643861 RAD 1802: Pilot Trial of LINAC Based Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
NCT05265715 A Low AGE (Advanced Glycation End-product) Dietary Intervention for Breast Cancer Survivors
NCT04628988 A Study of CC-90011 and Comparators in Participants With Prostate Cancer
NCT05130840 Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer
NCT03933670 Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
NCT03025035 Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
NCT05140252 Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid
NCT05183126 Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer
NCT00703105 Ovarian Dendritic Cell Vaccine Trial
NCT04141995 FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
NCT03272334 Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
NCT05470699 RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer
NCT04508764 Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome
NCT04895761 Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
NCT04770714 Prospective Comparison of Breast MRI vs Contrast Mammography Prior to Surgery in Breast Cancer Patients
NCT04493034 Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer
NCT04594473 A Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Among Breast Cancer Survivors
NCT03413332 Web-Based Communication Education for Breast Cancer Survivorship Care
NCT05384535 Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
NCT04633252 M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
NCT03324425 Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer
NCT03400215 Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer
NCT02035787 Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
NCT03820141 Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
NCT05042687 Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer
NCT04040569 A Phase I Dose Escalation Study of Single Fraction Ablative Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer
NCT05243641 Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
NCT03822494 CyberKnife Dose Escalation Prostate Cancer Trial
NCT04354675 Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast Cancer
NCT04495257 A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
NCT02977468 Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT03712813 Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors
NCT04796220 Focused Ultrasound and Gemcitabine in Breast Cancer
NCT04763980 Community-Based Health Coach to Improve Access to Germline Genetic Testing Among African American Men With Prostate Cancer
NCT05160597 Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
NCT05067777 Massage for Prostate Cancer-Related Fatigue, mPROSTATE Study
NCT04805333 Phase 1 Dose Escalation of ArtemiCoffee
NCT03998618 Telephone Support for Metastatic Breast Cancer Patients
NCT02958774 Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation
NCT03413995 Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
NCT05176470 Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
NCT03632941 A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer
NCT03802851 HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer
NCT04373031 Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
NCT04337580 Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
NCT04562233 Breast Cancer and Resistance Exercise Program
NCT03699995 MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
NCT04990921 Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
NCT05169957 Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
NCT02706561 Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
NCT01035112 Magnetic Resonance Imaging of Breast Cancer
NCT04243616 Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
NCT03808077 The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer
NCT04427527 Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia
NCT04020575 Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
NCT04444622 Immunotherapy for Third Line Metastatic Colorectal Cancer
NCT03436745 The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
NCT04891068 BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
NCT04523857 ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
NCT04857502 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
NCT04957290 A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
NCT05216120 Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas
NCT02807597 Real-time Intraoperative Breast Cancer Visualization for Margin Assessment
NCT04364672 Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Breast Cancer
NCT03492671 Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
NCT05305924 Fulvestrant Plus Abemaciclib With or Without Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
NCT04266431 EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression
NCT03873818 Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
NCT01913106 HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
NCT04763174 An mHealth Symptom Management Intervention for Colorectal Cancer Patients (mCOPE)
NCT05155033 Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
NCT04458532 Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
NCT04331067 Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
NCT04205786 Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer
NCT04332588 Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
NCT04709276 A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
NCT04389281 X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
NCT02732171 PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
NCT03933813 Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients
NCT04968964 Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
NCT03032406 CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
NCT05388877 E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
NCT04853043 Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
NCT04748042 Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
NCT05029999 CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer
NCT04427293 Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
NCT03711890 Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer
NCT02227654 Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors
NCT05156372 Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients
NCT04450706 Functional Precision Oncology for Metastatic Breast Cancer
NCT05036096 Cone Beam Breast CT for Breast Cancer Screening
NCT05071937 ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
NCT04941430 7T MRI Scan for the Early Detection of Melanoma Brain Metastases
NCT05351424 AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
NCT04091750 Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
NCT04273555 Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
NCT04190056 Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer
NCT04111510 Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
NCT04751929 Abemaciclib With or Without Atezolizumab for mCRPC
NCT05411094 Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
NCT05423730 Alcohol and Breast Cancer (ABC) Trial
NCT03962647 A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer
NCT04846478 Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
NCT05082025 Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
NCT04352777 Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
NCT05251038 Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
NCT05479578 Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT05130801 A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
NCT04272801 Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER+ Breast Cancer
NCT04090528 pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
NCT04568616 Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)
NCT04542135 Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
NCT02935205 Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
NCT04698564 Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
NCT04690855 A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer
NCT02613650 A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers
NCT03043794 Study of Stereotactic Radiotherapy for Breast Cancer
NCT05010200 The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.
NCT04573231 Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
NCT05225363 Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
NCT03821246 Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
NCT05233800 mHealth for Breast Cancer Survivors With Insomnia
NCT05011799 Health Education Intervention for Genetic Evaluation for Prostate Cancer Among African American Men, The Peer Genetic Study
NCT04725903 Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
NCT04965688 Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition
NCT04645680 Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study
NCT03801369 Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT05245006 PET Imaging Study of 89Zr-DFO-YS5
NCT05139368 Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
NCT04123704 Sitravatinib in Metastatic Breast Cancer
NCT05014295 Patient Recall of Cancer Screening and Diagnosis
NCT05077137 A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
NCT04837118 Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study
NCT03671811 Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
NCT03601923 Niraparib in Patients With Pancreatic Cancer
NCT04753359 Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
NCT05035836 A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
NCT05472792 Comparison of Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN)
NCT05576896 Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
NCT03835819 A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
NCT04134884 Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
NCT04697576 Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma
NCT03889795 Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
NCT02435472 Active Surveillance Exercise Clinical Trial
NCT04491955 Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers
NCT04634539 Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
NCT05013255 Pioglitazone Therapy Targeting Fatigue in Breast Cancer
NCT03085043 Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer
NCT03854903 WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
NCT05447923 Addressing Disparities in Colorectal Cancer Screening in Black and Underserved Phoenix Communities
NCT05226663 A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer
NCT05132296 Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer
NCT04267796 Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women
NCT05480306 Phase 2 Study of DKN-01 in Colorectal Cancer
NCT04469764 Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NCT04119024 Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma
NCT04703426 Sargramostim (GM-CSF) + PD-1
NCT04245176 Genetic Testing for All Breast Cancer Patients (GET FACTS)
NCT05055843 Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer
NCT04721886 Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer
NCT04913064 Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer
NCT04251416 A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
NCT04375527 Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
NCT05325151 Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer
NCT03021460 Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT03719131 Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
NCT05325632 Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
NCT03945721 A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
NCT03580499 Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy
NCT05036109 DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease
NCT02070705 DCE MRI in Patients With Pancreatic Cancer
NCT05081492 CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
NCT03822312 A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy
NCT04098081 1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
NCT04720209 Taking AIM at Breast Cancer
NCT05408260 A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer
NCT04886986 225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC
NCT03661424 BATs in Patients With Breast Cancer and Leptomeningeal Metastases
NCT03679559 Exercise in Improving Health and Quality of Life in Breast Cancer Survivors
NCT04256941 Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
NCT05200442 A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
NCT04896073 Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
NCT03675893 Abemaciclib With Letrozole in Recurrent or Persistent Endometrial Cancer
NCT04824027 Breast Elasticity Imaging During Neoadjuvant Chemotherapy
NCT04506567 Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC
NCT04207255 Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
NCT05198843 Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
NCT05391126 GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
NCT04139902 Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
NCT05225428 Video Education With Result Dependent dIsclosure
NCT03977233 Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
NCT02600949 Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
NCT04821375 Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers
NCT03657108 CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation
NCT04336943 Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
NCT04674306 Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
NCT03439735 Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
NCT04482244 RCT of CBD for Anxiety in Advanced Breast Cancer
NCT04363164 Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT05607004 (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT03703492 Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
NCT04533763 Living WELL: A Web-Based Program for Ovarian Cancer Survivors
NCT04866810 The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
NCT05305365 Study Assessing QBS72S For Treating Brain Metastases of Triple Negative Breast Cancer
NCT02681549 Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
NCT05524584 Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
NCT03650894 Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
NCT04620603 Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
NCT05497531 Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
NCT05150652 Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
NCT04486755 Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
NCT04457232 Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
NCT03569280 Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
NCT05168618 Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
NCT02884648 Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
NCT04886531 Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers
NCT05496959 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
NCT03677739 Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families
NCT02334579 Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer
NCT04174352 FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
NCT05278871 Noninvasive Assessment of Lymphedema Among Breast Cancer Survivors
NCT05467891 Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT03833921 Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
NCT03955627 REJOIN Trial for Older Breast Cancer Survivors
NCT04978675 An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer
NCT04013854 Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
NCT02064673 Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
NCT05043532 Randomized Trial for Optimal Number of Passes Required for Molecular Profiling During EUS-FNB of Pancreatic Cancer
NCT05161260 Breathwork App for Cancer Survivors
NCT05386719 Cardiometabolic Screening Program
NCT03847311 Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients
NCT03936478 Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
NCT00969111 Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
NCT04386057 LY3214996 +/- HCQ in Pancreatic Cancer
NCT04693338 Interactive Care Plan for the Monitoring of Symptoms and Recovery in Patients With Stage 0-III Breast Cancer
NCT03407417 A Patient-centered Intervention Using Technology to Reduce Colorectal Cancer Disparities in Primary Care
NCT05376878 An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
NCT04454528 BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
NCT04493333 Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors
NCT05069038 Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
NCT03275974 Glutamine PET Imaging Colorectal Cancer
NCT04738292 Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
NCT04887805 Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
NCT03703063 Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
NCT04203641 L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
NCT05034627 Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT04365569 Evaluating the Effectiveness of an Individualized Nutrition and Physical Activity Counseling Program
NCT04923542 Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
NCT04724499 Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy
NCT04716725 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
NCT04265872 Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
NCT04926181 Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
NCT02793921 Exercise Program in Cancer and Cognition
NCT04870515 Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study
NCT02599662 Intraoperative Radiation Therapy for Resectable Pancreas Cancer
NCT03825289 Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
NCT04998682 Prospective Evaluation of Targeted Axillary Dissection (TAD)
NCT04734730 Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
NCT04777071 An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer
NCT05557877 Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
NCT04636710 Refining Local-Regional Therapy for IBC
NCT05233059 FitEx for Endometrial Cancer Survivors
NCT03292198 Subclinical Lymphedema Treatment Study
NCT04267887 Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
NCT05054296 Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
NCT03873805 PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
NCT02871726 Transrectal Ultrasound Robot-Assisted Prostate Biopsy
NCT03769415 Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
NCT04753879 Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
NCT04116073 INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
NCT05438563 MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Intermediate Grade Prostate Cancer
NCT04123470 A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
NCT03012230 Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer
NCT04539808 NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
NCT03263429 Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
NCT04983342 Apollo Device for Metastatic Breast Cancer (MBC)
NCT01802346 Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer
NCT03902951 Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
NCT02204098 Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
NCT04631744 Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
NCT02965755 Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins
NCT04215029 Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans
NCT04985565 Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer
NCT04066361 OPTimizing Treatment Focused Genetic Testing IN Cancer
NCT03543189 Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
NCT02106598 Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases
NCT05483023 18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy
NCT03987217 Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients
NCT03727789 CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
NCT03175432 Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
NCT02905578 A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
NCT05413421 Study of ORIC-944 in Patients With Metastatic Prostate Cancer
NCT03458234 RAD 1801: Pilot Study of Intra-Urethral Radiotransponder Beacon Guided Focal Prostate Stereotactic Body Radiotherapy
NCT03725761 IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
NCT04888975 A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery
NCT04106856 Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)
NCT03460067 Omission of Radiation in Patients With Her-2 Positive Breast Cancer
NCT04995978 Insulin Resistance and Androgen Deprivation Therapy
NCT04837209 Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT04668976 A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
NCT03856658 Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
NCT05447910 Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT04379414 YES Study - Newly Diagnosed/Metastatic Intervention
NCT01985828 CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
NCT05436808 Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer
NCT04587128 Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
NCT02476786 Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT04947254 Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
NCT03285412 CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
NCT04356729 A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
NCT03899987 Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
NCT04658849 Insulin Resistance Following ADT for Prostate CA
NCT05505045 Metacognitive Strategy Training in Cancer-related Cognitive Impairment
NCT03440554 Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization
NCT05036681 A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
NCT04305834 Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
NCT05045066 Differences in Immunological Effects of Vitamin D Replacement Among African American Prostate Cancer Patients With Localized Versus Metastatic Disease
NCT03772834 Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer
NCT04614194 Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
NCT05281471 Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)
NCT04263025 AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
NCT04120246 Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
NCT05219695 Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)
NCT02531932 Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
NCT05323955 Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
NCT04955743 Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
NCT04973930 Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer
NCT02229084 Vaccination of High Risk Breast Cancer Patients
NCT04088708 Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors
NCT04727632 [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
NCT05551117 MGC018 Versus Androgen Receptor Axis-targeted Therapy in Participants With Metastatic Castration Resistant Prostate Cancer
NCT04191421 Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
NCT05560685 SMART-ER: Symptom Monitoring With Patient-reported Outcomes
NCT04947917 Axillary Lymph Node Tattoo Marking Study
NCT04493060 Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
NCT02538484 Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects
NCT05155046 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
NCT04150042 A Study of Melphalan, BCNU, Vitamin B12b, Vitamin C, and Stem Cell Infusion in People With Advanced Pancreatic Cancer and BRCA Mutations
NCT04731844 Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
NCT04318028 An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate Cancer
NCT05121545 Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors
NCT05525806 Clinical Utility Study for MyProstateScore+
NCT05381103 PSMA-PET to Guide Prostatectomy
NCT03503344 Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With Castration-Resistant Prostate Cancer (PILLAR)
NCT05043012 Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
NCT05038332 Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
NCT04982536 Assessment of VMCore Biopsy Versus Standard of Care Biopsy
NCT03999515 Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
NCT03033225 Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
NCT04867603 Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions
NCT03685331 HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
NCT05384119 Study of TTI-101 in Combination for Participants With Metastatic Hormone Receptor-Positive and Human Epithelial Receptor 2 (HER2)-Negative Breast Cancer
NCT04607135 ARFI Imaging for Targeted Prostate Biopsy
NCT04940299 Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
NCT05113537 Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
NCT04394676 The Impact of Low Pressure Pneumo in RARP II
NCT03269526 BATs Treatment for Pancreatic Cancer, Phase Ib/II
NCT04656678 Preliminary Effectiveness of Focal US-guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Locally Confined Intermediate Risk Prostate Cancer
NCT05176756 RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)
NCT01984138 REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
NCT02400658 Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer
NCT04477343 A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT03606486 Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer
NCT04908254 A Multi-center Randomized Control Cross-over Study to Evaluate the Safety and Effectiveness of the Dayspring Active Wearable Compression Device vs. an Advanced Pneumatic Compression Device for Treating Breast Cancer Related Lymphedema
NCT02290834 Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
NCT04233385 Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery
NCT03546686 Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer
NCT03575832 Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners
NCT04648904 Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
NCT04348747 Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
NCT05243862 Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
NCT03608631 iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
NCT02307058 Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy
NCT03995082 Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey
NCT03824652 WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
NCT05617755 AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
NCT04030559 Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
NCT04750473 Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer
NCT05340673 Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer
NCT05183295 Medical Food for the Dietary Management of Metastatic Colorectal Cancer
NCT04986579 Scalp Cooling in MBC
NCT03449108 LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
NCT04305236 Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer
NCT04871139 An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer
NCT05230810 Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
NCT04521764 A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
NCT03983577 Efficacy of Point Of Service Testing in MBC
NCT05037500 Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer
NCT03120624 VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer
NCT05591547 Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr
NCT04049214 Perioperative Mindfulness Proposal
NCT03387553 HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
NCT04030507 Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NCT05361174 A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
NCT04761614 Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT05422794 Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT05114798 Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
NCT05025059 Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer
NCT03880422 Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
NCT03990610 An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction
NCT05167409 A Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
NCT03012399 Hypnosedation in Relaxing Patients Undergoing Breast Cancer Surgery
NCT04715958 Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation
NCT04848337 Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
NCT05243056 A Quality of Life Intervention (Y-AMBIENT) for Young African American With Stage I-III Breast Cancer
NCT03844750 Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery
NCT04692818 3D Ultrasound Breast Imaging
NCT03955991 VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer)
NCT04791384 Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
NCT04290897 Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors
NCT04754412 Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study
NCT05049746 Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy
NCT03812393 Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast
NCT04717050 Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity
NCT03424850 Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
NCT04849871 Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma
NCT03785288 Vaginal Cuff Brachytherapy Fractionation Study
NCT03366155 Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
NCT04576871 Re-treatment 225Ac-J591 for mCRPC
NCT04249622 Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer
NCT05298605 Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women
NCT05364450 Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors
NCT03806738 Enhancing Shared Decision-Making in Breast Cancer
NCT04207359 Effects of Creatine Supplementation in Breast Cancer Survivors
NCT04022772 Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer
NCT05095207 Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
NCT02957981 The Genetic Education for Men Trial: Web-Based Education vs. Standard Care
NCT04454086 Exercise and Diet Counseling Program in Improving Quality of Life in Stage I-III Breast Cancer Survivors
NCT04445844 INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
NCT02436993 Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
NCT05631873 Colonoscopy Screening: Setting Epic Follow-up Times
NCT05471414 IIT Whole-Food Plant-Based Diet (WFPBD)
NCT04870034 Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer
NCT04875728 The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma
NCT04049695 Improving Cognition After Cancer
NCT05251714 CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT04524702 Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
NCT04890054 Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC
NCT03796559 Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
NCT04139993 RBX7455 Before Surgery for the Treatment of Operable Breast Cancer
NCT02754752 Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment
NCT04205903 Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
NCT05092477 Integrated Intervention for Breast Cancer Survivors With Diabetes
NCT04090567 Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT02515110 Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
NCT04719273 Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
NCT00625417 Optical Spectroscopy in Evaluating Tumor Margins in Patients Who Have Undergone Surgery for Breast Tumors
NCT05455658 STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
NCT04754425 Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
NCT03987386 Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
NCT04535323 Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer
NCT05319873 Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
NCT01174121 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT03554083 NeoACTIVATE: Neoadjuvant Therapy for Patients With High Risk Stage III Melanoma
NCT03554044 T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
NCT04499950 Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study
NCT04673448 Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
NCT04471974 ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT03298945 Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens
NCT05177796 Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
NCT04645810 A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
NCT03803553 Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
NCT05162846 Methods for Increasing Genetic Testing Uptake in Michigan
NCT04592237 Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
NCT04374747 Fruit and Vegetable Intervention in Lactating Women to Reduce Breast Cancer Risk
NCT05473026 Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors
NCT03897270 Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects
NCT04951492 Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
NCT03535727 A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
NCT04428905 Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer
NCT03796767 Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
NCT05183828 Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-II Breast Cancer
NCT04677816 Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
NCT03657069 Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy
NCT04267939 ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
NCT05204147 Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Positive Advanced Colorectal Cancer
NCT03216421 Intraoperative Radiation Therapy (IORT) in DCIS
NCT05453630 Colonoscopy Outreach for Rural Communities Aim 2
NCT04016376 Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction
NCT03442556 Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
NCT04839614 Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT04762979 Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
NCT03698162 Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
NCT05245812 Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
NCT04843306 Breath-Hold Technique for Pancreatic Stereotactic Body Radiation Therapy (SBRT) Patients
NCT03999749 A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NCT03844620 Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
NCT05508906 Phase 1b Combo w/ Ribociclib and Alpelisib
NCT04796818 An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response
NCT04789486 Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
NCT04481113 Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
NCT04484909 NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
NCT05130060 A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer
NCT04085510 Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania
NCT03572283 Bethanechol Prior to Pancreatic Surgery
NCT05141513 Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma
NCT02535078 Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma
NCT04616183 LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
NCT04017650 Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
NCT02912572 Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
NCT03991962 Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
NCT03910387 Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
NCT05286814 M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
NCT03704662 Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
NCT03087071 Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
NCT02863783 EUS Fiducial for Pancreas Surgery
NCT05200559 T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors
NCT02451982 Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
NCT04599218 MR/TRUS Fusion Guided Prostate Biopsy - An Improved Way to Detect and Quantify Prostate Cancer
NCT04253483 Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
NCT04485767 RESIST-ADT (Androgen Deprivation Therapy)
NCT05360680 A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
NCT05254171 Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT03384836 Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
NCT04616534 Testing the Addition of an Anti-cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
NCT02949284 Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
NCT05086705 EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer
NCT04683315 PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
NCT02689427 Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
NCT04777786 Early Rehabilitation for Breast Cancer - A Randomized Control Trial
NCT05032040 A Study of XmAb20717 in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
NCT04390399 Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT05327608 Intermittent Fasting for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery
NCT02946697 A Culturally Sensitive Social Support Intervention
NCT03449238 Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT02672917 Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
NCT04763902 Time Restricted Eating (TRE) Among Native Hawaiian/Pacific Islander Women at Risk for Endometrial Cancer
NCT04927663 11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer
NCT04940286 Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
NCT03213041 Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
NCT04705363 A Sociolinguistic-enabled Web Application to Develop Precision Health Intervention for African Americans
NCT05041101 Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
NCT04461509 High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
NCT03955510 Abnormal Food Timing and Circadian Dyssynchrony in Alcohol Induced Colon Carcinogenesis
NCT04959474 SABR-CaRe in Early Stage Breast Cancer
NCT04763824 KanSurvive: Testing a Model for Improving Cancer Survivorship Care in Rural Practice
NCT03737370 Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
NCT04313114 The PRIME-CRC Trial to Promote CRC Screening in Rural Communities
NCT03345420 Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
NCT03640208 Educate, Assess Risk and Overcoming Barriers to Colorectal Screening Among African Americans
NCT03768492 Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy
NCT04915508 Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
NCT03550885 Diet Modulation of Bacterial Sulfur and Bile Acid Metabolism and Colon Cancer Risk
NCT05241249 Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
NCT05038137 Time Restricted Eating on Cancer Risk
NCT04711161 First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
NCT04763915 Improving Care After Inherited Cancer Testing
NCT05012176 An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors
NCT04333706 A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
NCT05094102 Intraoperative Evaluation of Axillary Lymphatics
NCT05365893 PHL Treatment in Pancreatic Cancer
NCT03146962 High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies
NCT03484299 Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
NCT02598349 Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
NCT04407247 Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
NCT05055323 A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
NCT04005690 Targeted PARP or MEK/ERK Inhibition in Patients With Pancreatic Cancer
NCT03540017 HIPEC After Initial CRS in Patients Who Have Received NACT
NCT04750941 Study of Copanlisib and Ketogenic Diet
NCT03202316 Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
NCT02452008 Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
NCT04990609 Endoscopic Ultrasound PANcreatic CAncer RaDIofrequeNcy AbLation
NCT04981834 Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer
NCT02830724 Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT03592888 DC Vaccine in Pancreatic Cancer
NCT04646434 Brain and Pelvic Floor Muscle Activity of Patients Undergoing Robot-Assisted Radical Prostatectomy
NCT05548296 A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
NCT05010759 Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer
NCT03716739 Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
NCT04861896 A Research Study for Latina Women With Breast Cancer
NCT04396808 Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
NCT04599140 SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
NCT04194554 A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
NCT02484404 Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
NCT03701581 4-aminopyridine Treatment for Nerve Injury
NCT03796273 Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
NCT05366842 Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care
NCT04304001 Test Up Now Education Program
NCT03073785 Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic Cancer
NCT03907527 Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT04975217 Fecal Microbial Transplants for the Treatment of Pancreatic Cancer
NCT03885284 Study of Proton Therapy in Adjuvant Pancreatic Cancer
NCT03507608 Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
NCT02411656 Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
NCT05114421 Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
NCT03865875 Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program
NCT05233696 Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC
NCT05456685 IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer
NCT05289830 Escitalopram to Placebo in Patients With Localized Pancreatic Cancer
NCT05375604 A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Primary Gastric Cancer and Colorectal Cancer (CRC)
NCT05335993 A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
NCT02335671 Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy
NCT04594772 Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
NCT03732950 Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
NCT04606914 Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05077800 FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer
NCT03851237 CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
NCT04387071 CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
NCT05588609 Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
NCT05241613 A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT05098327 Pioglitazone and Insulin Resistance in ADT
NCT04491591 Implementing BREASTChoice Into Practice
NCT04965311 Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy
NCT04143516 Tissue Analysis After Thermal Ablation for Colon Cancer Liver Metastases Leading to Immediate Retreatment
NCT05271318 Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Ovarian Cancer
NCT02095184 GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
NCT04976257 Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
NCT04305145 Infliximab for Treatment of Ipilimumab Colitis
NCT05142358 A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose
NCT03025256 Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
NCT03975491 The Exercise And Colorectal Cancer Treatment Trial
NCT04879940 Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
NCT03642067 Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
NCT04514692 Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
NCT02124421 HOT: HIPEC in Ovarian Cancer as Initial Treatment
NCT03781154 Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors
NCT03008408 A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
NCT04670445 Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
NCT01794403 Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer
NCT05080842 A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer
NCT01407263 Trial of Modifications to Radical Prostatectomy
NCT03428581 Preventing Lymphedema in Axillary Lymph Node Dissection
NCT03419585 The "PC-LIGHT" Study
NCT05296421 Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
NCT04662879 Early Detection Initiative for Pancreatic Cancer
NCT02422641 Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT04234386 GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
NCT05336266 A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
NCT04936243 TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance)
NCT03446157 Palbociclib and Cetuximab in Metastatic Colorectal Cancer
NCT05386108 Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
NCT04527900 The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
NCT03573648 Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
NCT03290677 Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-progression Immune Checkpoint Inhibitor Therapy
NCT04906200 Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors
NCT04862585 Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
NCT03878849 Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®
NCT05301114 Social Risk Factors and Discrimination in Cancer Survivorship
NCT03784677 SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors
NCT04696263 Single-Port Versus Multi-Port Robotic Radical Prostatectomy
NCT04896320 Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.
NCT04764292 Screening Contrast-Enhanced Mammography as an Alternative to MRI
NCT01712815 PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer
NCT02891538 Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients
NCT04993313 Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study
NCT05039801 IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors
NCT05040568 A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
NCT04329065 Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT05455619 Evexomostat Plus Alpelisib and Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia With Breast Cancer
NCT05464810 Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT03789097 Vaccination With Flt3L, Radiation, and Poly-ICLC
NCT05451849 A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
NCT05366699 LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy
NCT05130580 Patient-Specific Decision Aid System for Shared Decision Making About Breast Reconstruction
NCT04925817 3D Ultrasound Microvessel Imaging for Breast Masses
NCT05103683 First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05086731 Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer
NCT04849858 Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures
NCT01239095 Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing Resection
NCT05412953 Tonation Breathing Technique Method to Ease Aromatase Inhibitor-induced Joint and/or Muscle Pain
NCT05296512 Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
NCT04943536 Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
NCT03654638 Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer
NCT05163223 Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
NCT04175431 Fluciclovine (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
NCT04683731 Helping Patients and Providers Make Better Decisions About Colorectal Cancer Screening
NCT04294225 Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
NCT05368428 Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer
NCT04946370 Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC
NCT05322590 BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
NCT05413850 Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT04514484 Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
NCT04837833 An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma
NCT05056077 Improving Nutrition and Physical Activity for Colorectal Cancer Survivors (Tools To Be Fit)
NCT04905082 HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
NCT01492972 Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
NCT03983993 Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
NCT04899908 Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Research Search Tool Sponsored By:

Merck & Co., Inc.
Mike & Patti Hennessy Foundation